Recent research have converged on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine communication. While GLP stimulators are widely employed for addressing type 2 T2DM, their potential impacts on motivation circuits, specifically me